Richard MOREAU
  • E-mail :[email]
  • Phone : 33 1 57 27 75 10
  • Location : UMR_S 1149, Centre de Recherche sur l’Inflammation CRI, 16 Rue Henri Huchard 75890 PARIS cedex 18 Paris, France
Last update 2023-02-03 12:50:54.876

Richard MOREAU MD, Senior Scientist at the National (French) Institute of Health (Inserm)

Course and current status

Current address: UMR_S 1149, Centre de Recherche sur l’Inflammation CRI, Inserm et Université Paris Diderot – Site Bichat, 16 Rue Henri Huchard 75890 PARIS cedex 18, France
E-mail address:


ResearcherID: N-2197-2017

 Current Positions:

1) Chairman of the Scientific Advisory Board of the European Foundation for the Study of Chronic Liver Failure (EF CLIF), Barcelona, Spain

2) Honorary Director, Grifols Chair, European Foundation for the Study of Chronic Liver Failure (EF CLIF, Barcelona, Spain

3) Emeritus Senior Scientist at the INSERM (French NIH)

4) Consultant in Hepatology, Liver Unit, Beaujon Hospital (Head Prof F Durand), Assistance Publique Hôpitaux de Paris (APHP), Clichy, France

Current affiliations:

1) European Foundation for the Study of Chronic Liver Failure (EF CLIF), Barcelona, Spain

2) Centre de Recherche sur l’Inflammation CRI, INSERM and Université Paris Cité, Paris, France

3) Service d'hépatologie, Hôpital Beaujon APHP, Clichy, France



1983: MD, University of Paris

Academic Positions: 

  • 2019-Date: Emeritus Senior Scientist at the INSERM
  • 2014-2018: Senior Scientist: “Directeur de Recherche de Classe exceptionnelle (DRCE)" at the INSERM
  • 2009-2013: Senior Scientist: "Directeur de Recherche de 1ere classe" at the INSERM
  • 1996-2008: Senior Scientist: "Directeur de Recherche de 2eme classe" at the INSERM
  • 2013-2020: Co-Chairman, with Prof. Shiv Sarin (Institute of Liver and Biliary Sciences, ILBS, New Delhi, India) of an International Associated Laboratory entitled “ILBS Associated Laboratory for the Development of Indo-French Research on Severe Liver Diseases”
  • 2014-2020: Adjunct Professor, Institute of Liver and Biliary Sciences, ILBS, New Delhi, India
  • 2014-2018: Vice-Chairman, Centre de Recherche sur l’Inflammation CRI, UMR_S1149, Inserm and Université Paris-Diderot, Paris 7, Clichy/Paris, France.
  • 2013: Chairman, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, UMR_S 773, Inserm and Université Paris-Diderot, Paris 7, Clichy/Paris.
  • 2005-2018: Head of Team (Complications of cirrhosis) at the Centre de Recherche Biomédicale Bichat-Beaujon CRB3, UMR_S 773, Inserm and Université Paris-Diderot, Paris 7, Clichy/Paris, France.
  • 1996-2004: Head of group in the Lebrec’s lab (successively in Inserm Units 24 and 481), Clichy, France


Hospital Positions:

  • 1996-Date: Consultant in Hepatology, Liver Unit, Beaujon Hospital (successively Headed by Profs J-P Benhamou, S Erlinger, D Valla, and F Durand), Assistance Publique Hôpitaux de Paris (APHP), Clichy, France
  • 1983-1996: Physician in Intensive Care Units of Ile-de-France 

Other Positions

  • 2016-2021: Deputy Director, Grifols Chair, European Foundation for the Study of Chronic Liver Failure (EF CLIF)
  • 2009-2018: Member of the Steering Comittee of the Consortium EASL-CLIF (for Chronic Liver Failure); Principal Investigator of the CANONIC Study on Acute-on-Chronic Liver Failure.
  • 2009: Founding member of the EASL-CLIF (Chronic Liver Failure) Consortium
  • 2010-2013: Member of the SC of the Special Interest Group on Portal Hypertension of the American Association for the Study of Liver Diseases

Society Membership: 

  • American Association for the Study of Liver Diseases (AASLD)
  • European Association for the Study of the Liver (EASL)
  • Asian Pacific Association ofr the Study of the Liver (APASL)
  • French Speaking Society of Intensive Care Medicine
  • French Association of the Study of the Liver
  • International Ascites Club (Scientific Committee, 1994-2003)
  • French Club for the Study of Portal Hypertension


  • 2009: Colombian Socitety of Gastroenterology
  • 2014: Award Scientific Excellence (Inserm)
  • 2015: Czech Society for the Study of the Liver
  • 2019: “Special Price” by the Club Francophone de l’Etude de l’Hypertension Portale
  • 2022: Fellow of the American Association for the Study of Liver Diseases (AASLD)

Editorial Activities:

Boards of Editors

  • 2020-21: Special Section Editor, Journal of Hepatology
  • 2015-2019: Senior Editor, Journal of Hepatology 
  • 2010-2014: Associate Editor, Journal of Hepatology
  • 2007-September 2009: Associate Editor, Liver International
  • 2001-2008: Co-Editor: Gastroentérologie Clinique et Biologique
  • 1997-2001: Associate Editor, Gastroentérologie Clinique et Biologique


Editorial Boards

  • 2020-Date: Editorial Board, Gastroenterology
  • 2011-2014: Editorial Board, Hepatology
  • 2007-2009: Editorial Board, Journal of Hepatology
  • 2002-2006: Editorial Board, Hepatology


French Organization of Research:

  • 2008-Date: Expert (Liver Branch) at the Aviesan Institute 'Pathophysiology, Metabolism, Nutrition' (Head, Prof C. Boitard).
  • 2010-2017: Elected as Member of the Council advising the Dean of the Faculty of Medicine, University Paris Diderot, Paris  
  • 2013-2018: Member of the Steering Committee (SC) of the 'Département Hospitalo-Universitaire' (DHU) UNITY (for Addressing Unmet Needs through Innovation in HepaTology and GastroenterologY), Beaujon Hospital, APHP, Clichy
  • 2012-Date: Partner of the 'Laboratoire d’excellence (Labex)' Inflamex, ComUE Sorbonne Paris Cité, Paris. 

Scientific Production:

  • 418 Peer-Reviewed publications (PubMed, updated October 2022), including 262 Original Articles, 156 Review Articles or Editorialsh-index: 82 (Web of Sciences, Clarivate Analytics); h-index: 100 (Google Scholar); SIGAPS (French index): 6350 (1985-Date).
  • Editor of 1 book
  • 35 book chapters,
  • 300 Invited lectures, 350 communications in International meetings

Representative publications (past 10 years)

  1. Arroyo V, Moreau R, Jalan R. Acute-on-Chronic Liver Failure. N Engl J Med. 2020 May 28;382(22):2137-2145.
  2. Weiss E, de la Grange P, Defaye M, Lozano JJ, Aguilar F, Hegde P, Jolly A, Moga L, Sukriti S, Agarwal B, Gurm H, Tanguy M, Poisson J, Clària J, Abback PS, Périanin A, Mehta G, Jalan R, Francoz C, Rautou PE, Lotersztajn S, Arroyo V, Durand F, Moreau R. Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. Front Immunol 2021 Feb 5;11:619039.PMID: 33613548.
  3. Arroyo V*, Angeli P*, Moreau R*, Jalan R*, Claria J, Trebicka J, Fernández J, Gustot T, Caraceni P, Bernardi M; investigators from the EASL-CLIF Consortium, Grifols Chair; European Foundation for the Study of Chronic Liver Failure (EFClif). The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis. J Hepatol. 2020 PMID: 33301825. *Co-first authors
  4. Zaccherini G, Aguilar F, Caraceni P, Clària J, Lozano JJ, Fenaille F, Castelli F, Junot C, Curto A, Formentin C, Weiss E, Bernardi M, Jalan R, Angeli P, Moreau R, Arroyo V. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. J Hepatol. 2020 Dec 1:S0168-8278(20)33821-6. doi: 10.1016/j.jhep.2020.11.035. Online ahead of print. PMID: 33276029.
  5. Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jansen C, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Jarcuska P, Steib C, Reiberger T, Acevedo J, Gatti P, Shawcross DL, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Danielsen KV, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solé C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Kani HT, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia-Lopez E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Praktiknjo M, Curto A, Pitarch C, Putignano A, Moreno E, Bernal W, Aguilar F, Clària J, Ponzo P, Vitalis Z, Zaccherini G, Balogh B, Gerbes A, Vargas V, Alessandria C, Bernardi M, Ginès P, Moreau R, Angeli P, Jalan R, Arroyo V; PREDICT STUDY group of the EASL-CLIF CONSORTIUM. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol. 2020 Nov 20:PMID: 33227350.
  6. Casulleras M, Flores-Costa R, Duran-Güell M, Alcaraz-Quiles J, Sanz S, Titos E, López-Vicario C, Fernández J, Horrillo R, Costa M, de la Grange P, Moreau R, Arroyo V, Clària J. Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis. Sci Transl Med. 2020 Oct 21;12(566):eaax5135.
  7. Moreau R, Clària J, Aguilar F, Fenaille F, Lozano J, Junot C, Colsch B, Caraceni P, Trebicka J, Pavesi M, Alessandria C, Nevens F, Saliba F, Welzel TM, Albillos A, Gustot T, Fernández J, Moreno C, Baldasarre M, Zaccherini G, Piano S, Montagnese S, Vargas V, Genescà J, Solà E, Bernal W, Butin N, Hautbergue T, Cholet S, Castelli F, Jansen C, Steib C, Campion D, Mookerjee R, Rodríguez-Gandía M, Soriano G, Durand F, Benten D, Bañares R, Stauber RE, Gronbaek H, Coenraad MJ, Ginès P, Gerbes A, Jalan R, Bernardi M, Arroyo V, Angeli P; CANONIC Study Investigators of the EASL Clif Consortium, Grifols Chair and the European Foundation for the Study of Chronic Liver Failure (EF Clif). Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol. 2019 Nov 25. PMID:31778751.
  8. Fernández J, Angeli P, Trebicka J, Merli M, Gustot T, Alessandria C, Aagaard NK, de Gottardi A, Welzel TM, Gerbes A, Soriano G, Vargas V, Albillos A, Salerno F, Durand F, Bañares R, Stauber R, Prado V, Arteaga M, Hernández-Tejero M, Aziz F, Morando F, Jansen C, Lattanzi B, Moreno C, Campion D, Gronbaek H, Garcia R, Sánchez C, García E, Amorós A, Pavesi M, Clària J, Moreau R, Arroyo V. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. Clin Gastroenterol Hepatol. 2019 Aug 5.  PMID: 31394283.
  9. Fernández J, Clària J, Amorós A, Aguilar F, Castro M, Casulleras M, Acevedo J, Duran-Güell M, Nuñez L, Costa M, Torres M, Horrillo R, Ruiz-Del-Árbol L, Villanueva C, Prado V, Arteaga M, Trebicka J, Angeli P, Merli M, Alessandria C, Aagaard NK, Soriano G, Durand F, Gerbes A, Gustot T, Welzel TM, Salerno F, Bañares R, Vargas V, Albillos A, Silva A, Morales-Ruiz M, Pavesi M, Jalan R, Bernardi M, Moreau R, Páez A, Arroyo V. Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology. 2019 Jul;157(1):149-162.
  10. Trebicka J, Amoros A, Pitarch C, Titos E, Alcaraz-Quiles J, Schierwagen R, Deulofeu C, Fernandez-Gomez J, Piano S, Caraceni P, Oettl K, Sola E, Laleman W, McNaughtan J, Mookerjee RP, Coenraad MJ, Welzel T, Steib C, Garcia R, Gustot T, Rodriguez Gandia MA, Bañares R, Albillos A, Zeuzem S, Vargas V, Saliba F, Nevens F, Alessandria C, de Gottardi A, Zoller H, Ginès P, Sauerbruch T, Gerbes A, Stauber RE, Bernardi M, Angeli P, Pavesi M, Moreau R, Clària J, Jalan R, Arroyo V. Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Front Immunol. 2019 Mar 19;10:476. PMID: 30941129.
  11. Clària J*, Moreau R*, Fenaille F, Amorós A, Junot C, Gronbaek H, Coenraad MJ, Pruvost A, Ghettas A, Chu-Van E, López-Vicario C, Oettl K, Caraceni P, Alessandria C, Trebicka J, Pavesi M, Deulofeu C, Albillos A, Gustot T, Welzel TM, Fernández J, Stauber RE, Saliba F, Butin N, Colsch B, Moreno C, Durand F, Nevens F, Bañares R, Benten D, Ginès P, Gerbes A, Jalan R, Angeli P, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL Clif Consortium Grifols Chair and the European Foundation for the Study of Chronic Liver Failure (EF Clif). Orchestration of Tryptophan-Kynurenine pathway, acute decompensation and acute-on-chronic liver failure in cirrhosis. Hepatology. 2019 Apr;69(4):1686-1701. *Co-first authors
  12. Moreau RElkrief L, Bureau C, Perarnau JM, Thévenot T, Saliba F, Louvet A, Nahon P, Lannes A, Anty R, Hillaire S, Pasquet B, Ozenne V, Rudler M, Ollivier-Hourmand I, Robic MA, d'Alteroche L, Di Martino V, Ripault MP, Pauwels A, Grangé JD, Carbonell N, Bronowicki JP, Payancé A, Rautou PE, Valla D, Gault N, Lebrec D; NORFLOCIR Trial Investigators. Effects of Long-term Norfloxacin Therapy in Patients with Advanced Cirrhosis. Gastroenterology. 2018 Dec;155(6):1816-1827.e9. 
  13. Gustot T, Moreau R. Acute-on-Chronic Liver Failure vs. Traditional Acute Decompensation of Cirrhosis. J Hepatol. 2018 Sep 6. PMID:30195459.
  14. Maras JS, Das S, Sharma S, Shasthry SM, Colsch B, Junot C, Moreau R*, Sarin SK*. Baseline urine metabolic phenotype in patients with severe alcoholic hepatitis and its association with outcome. Hepatol Commun. 2018 Apr 16;2(6):628-643. PMID:29881815. *Co-senior authors
  15. Hegde P, Weiss E, Paradis V, Wan J, Mabire M, Sukriti S, Rautou PE, Albuquerque M, Picq O, Gupta AC, Ferrere G, Gilgenkrantz H, Kiaf B, Toubal A, Beaudoin L, Lettéron P, Moreau R, Lehuen A, Lotersztajn S. Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nat Commun. 2018 Jun 1;9(1):2146. 
  16. Bajaj JS, Moreau R, Kamath PS, Vargas HE, Arroyo V, Reddy KR, Szabo G, Tandon P, Olson J, Karvellas C, Gustot T, Lai JC, Wong F. Acute-on-Chronic Liver Failure: Getting ready for prime-time. Hepatology. 2018 Apr 24.PMID:29689120.
  17. Sharma S, Maras JS, Das S, Hussain S, Mishra AK, Shasthry SM, Sharma CB, Weiss E, Elkrief L, Rautou PE, Gilgenkrantz H, Lotersztajn S, Paradis V, de la Grange P, Junot C, Moreau RSarin SK. Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness. Sci Rep. 2017 Jul 28;7(1):6816. PMID:28754919.
  18. Rolas L, Boussif A, Weiss E, Lettéron P, Haddad O, El-Benna J, Rautou PE, Moreau R, Périanin A. NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7/8 activation. Gut. 2017 Jun 10. PMID:28601846
  19. Markwardt D, Holdt L, Steib C, Benesic A, Bendtsen F, Bernardi MMoreau RTeupser D, Wendon J, Nevens F, Trebicka J, Garcia E, Pavesi M, Arroyo V, Gerbes AL. Plasma Cystatin C is a predictor of renal dysfunction, ACLF and mortality in patients with acutely decompensated liver cirrhosis. Hepatology. 2017 May 25. PMID:28545169
  20. Weiss E, Rautou PE, Fasseu M, Giabicani M, de Chambrun M, Wan J, Minsart C, Gustot T, Couvineau A, Maiwall R, Hurtado-Nedelec M, Pilard N, Lebrec D, Valla D, Durand F, de la Grange P, Monteiro RC, Paugam-Burtz C, Lotersztajn S, Moreau R. Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome. J Hepatol. 2016 Dec 28. PMID:28040548
  21. Hernaez R, Solà E, Moreau R*, Ginès P*. Acute-on-chronic liver failure: an update. Gut. 2017 Jan 4. pii: gutjnl-2016-312670. PMID:2805305. *Equally contributed
  22. Arroyo V, Moreau R. Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis. J Hepatol. 2016 Dec 15. PubMed PMID: 27989380.
  23. Clària J, Arroyo V, Moreau R. The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray. J Immunol. 2016 Nov 15;197(10):3755-3761. Review. 
  24. Clària J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, Amorós À, Titos E, Alcaraz-Quiles J, Oettl K, Morales-Ruiz M, Angeli P, Domenicali M, Alessandria C, Gerbes A, Wendon J, Nevens F, Trebicka J, Laleman W, Saliba F, Welzel TM, Albillos A, Gustot T, Benten D, Durand F, Ginès P, Bernardi M, Arroyo  V; CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF). Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology. 2016 Oct;64(4):1249-64. 
  25. Poisson J, Lemoinne S, Boulanger C, Durand F, Moreau R, Valla D, Rautou PE. Liver sinusoidal endothelial cells: physiology and role in liver diseases. J Hepatol. 2016 Jul 13. pii: S0168-8278(16)30333-6. 
  26. Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, Fernández J, To U, García-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. Nat RevDis Primers. 2016 Jun 9;2:16041. 
  27. Moreau R. The Pathogenesis of ACLF: The Inflammatory Response and Immune Function. Semin Liver Dis. 2016 May;36(2):133-40. 
  28. Jalan R, Moreau R, Kamath PS, Arroyo V. Acute-on-Chronic Liver Failure: A Distinct Clinical Condition. Semin Liver Dis. 2016 May;36(2):107-8. 
  29. Li H, Chen LY, Zhang NN, Li ST, Zeng B, Pavesi M, Amorós À, Mookerjee RP, Xia Q, Xue F, Ma X, Hua J, Sheng L, Qiu DK, Xie Q, Foster GR, Dusheiko G, Moreau R, Gines P, Arroyo V, Jalan R. Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B. Sci Rep. 2016 May 5;6:25487. 
  30. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016 Jul;36(7):936-48. 
  31. Boussif A, Rolas L, Weiss E, Bouriche H, Moreau R, Périanin A. Impaired intracellular signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis. J Hepatol. 2016 May;64(5):1041-8. 
  32. Nadim MK, Durand F, Kellum JA, Levitsky J, O'Leary JG, Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell SH, Fernández J, Francoz C, Garcia-Tsao G, Ginès P, Ison MG, Kramer DJ, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent JL, Genyk YS. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. J Hepatol. 2016 Mar;64(3):717-35. 
  33. Nahon P, Lescat M, Layese R, Bourcier V, Talmat N, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP,  Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L,  Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Trinchet JC, Moreau R, Roudot-Thoraval F; ANRS CO12 CirVir and Microcir Groups. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospectivecohort). Gut. 2015 Oct 28. pii: gutjnl-2015-310275. doi: 10.1136/gutjnl-2015-310275. PubMed PMID: 26511797.
  34. Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, Chawla YK, Dokmeci AK, Garg H, Ghazinyan H, Hamid S, Kim DJ, Komolmit P, Lata S, Lee GH, Lesmana LA, Mahtab M, Maiwall R, Moreau R, Ning Q, Pamecha V, Payawal DA, Rastogi A, Rahman S, Rela M, Saraya A, Samuel D, Saraswat V, Shah S, Shiha G, Sharma BC, Sharma MK, Sharma K, Butt AS, Tan SS, Vashishtha C, Wani ZA, Yuen MF, Yokosuka O; APASL ACLF Working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int. 2014 Oct;8(4):453-71. 
  35. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015 Nov;63(5):1272-84. 
  36. Arroyo V, Moreau R, Jalan R, Ginès P; EASL-CLIF Consortium CANONIC Study. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. J Hepatol. 2015 Apr;62(1 Suppl):S131-43. 
  37. Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, Laleman W, Trebicka J, Elkrief L, Hopf C, Solís-Munoz P, Saliba F, Zeuzem S, Albillos A, Benten D, Montero-Alvarez JL, Chivas MT, Concepción M, Córdoba J, McCormick A, Stauber R, Vogel W, de Gottardi A, Welzel TM, Domenicali M, Risso A, Wendon J, Deulofeu C, Angeli P, Durand F, Pavesi M, Gerbes A, Jalan R, Moreau R, Ginés P, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL-CLIF Consortium. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015 Jul;62(1):243-52. 
  38. Jalan R, Pavesi M, Saliba F, Amorós A, Fernandez J, Holland-Fischer P, Sawhney R, Mookerjee R, Caraceni P, Moreau R, Ginès P, Durand F, Angeli P, Alessandria C, Laleman W, Trebicka J, Samuel D, Zeuzem S, Gustot T, Gerbes AL, Wendon J, Bernardi M, Arroyo V; CANONIC Study Investigators; EASL-CLIF Consortium. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol. 2015 Apr;62(4):831-40. Erratum in: J Hepatol. 2015 Jul;63(1):291. 
  39. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Muñoz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V; CANONIC study investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014 Nov;61(5):1038-47. 
  40. Arroyo V, Moreau R. Tying up PGE2 with albumin to relieve immunosuppression in cirrhosis. Nat Med. 2014 May;20(5):467-9. 
  41. Mehta G, Gustot T, Mookerjee RP, Garcia-Pagan JC, Fallon MB, Shah VH, Moreau R, Jalan R. Inflammation and portal hypertension - the undiscovered country. J Hepatol. 2014 Jul;61(1):155-63. 
  42. Durand F, Buyse S, Francoz C, Laouénan C, Bruno O, Belghiti J, Moreau R, Vilgrain V, Valla D. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol. 2014 Jun;60(6):1151-7. 
  43. Moreau R, Arroyo V. Acute-on-chronic liver failure: a new clinical entity. Clin Gastroenterol  Hepatol. 2015 May;13(5):836-41. 
  44. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs A, Ginès P. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014 Jun;60(6):1310-24. 
  45. Lemoinne S, Thabut D, Housset C, Moreau R, Valla D, Boulanger CM, Rautou PE. The emerging roles of microvesicles in liver diseases. Nat Rev Gastroenterol Hepatol. 2014 Jun;11(6):350-61. 
  46. Francoz C, Nadim MK, Baron A, Prié D, Antoine C, Belghiti J, Valla D, Moreau R, Durand F. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. Hepatology. 2014 Apr;59(4):1514-21. 
  47. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9. 
  48. Gandoura S, Weiss E, Rautou PE, Fasseu M, Gustot T, Lemoine F, Hurtado-Nedelec M, Hego C, Vadrot N, Elkrief L, Lettéron P, Tellier Z, Pocidalo MA, Valla D, Lebrec D, Groyer A, Monteiro RC, de la Grange P, Moreau R. Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. J Hepatol. 2013 May;58(5):936-48. 
  49. Rolas L, Makhezer N, Hadjoudj S, El-Benna J, Djerdjouri B, Elkrief L, Moreau R, Périanin A. Inhibition of mammalian target of rapamycin aggravates the respiratory burst defect of neutrophils from decompensated patients with cirrhosis. Hepatology. 2013 Mar;57(3):1163-71. 
  50. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, Arroyo V, Kamath PS. Acute-on chronic liver failure. J Hepatol. 2012 Dec;57(6):1336-48. 
  51. Sersté T, Gustot T, Rautou PE, Francoz C, Njimi H, Durand F, Valla D, Lebrec D, Moreau R. Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites. J Hepatol. 2012 Aug;57(2):274-80. 
  52. Rautou PE, Bresson J, Sainte-Marie Y, Vion AC, Paradis V, Renard JM, Devue C, Heymes C, Letteron P, Elkrief L, Lebrec D, Valla D, Tedgui A, Moreau R, Boulanger CM. Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology. 2012 Jul;143(1):166-76.e6. 
  53. Tissandié E, Morelle W, Berthelot L, Vrtovsnik F, Daugas E, Walker F, Lebrec D, Trawalé JM, Francoz C, Durand F, Moura IC, Paradis V, Moreau R, Monteiro RC. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int. 2011 Dec;80(12):1352-63. 
  54. Sersté T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, Moreau R*, Lebrec *D. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011 Oct;55(4):794-9.*Equal contributions
  55. Coant N, Simon-Rudler M, Gustot T, Fasseu M, Gandoura S, Ragot K, Abdel-Razek W, Thabut D, Lettéron P, Ogier-Denis E, Ouziel R, Devière J, Lizard G, Tellier Z, Lebrec D, Moreau R. Glycogen synthase kinase 3 involvement in the excessive proinflammatory response to LPS in patients with decompensated cirrhosis. J Hepatol. 2011 Oct;55(4):784-93. 
  56. Thabut D, Moreau R, Lebrec D. Noninvasive assessment of portal hypertension in patients with cirrhosis. Hepatology. 2011 Feb;53(2):683-94. 
  57. Francoz C, Prié D, Abdelrazek W, Moreau R, Mandot A, Belghiti J, Valla D, Durand F. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transpl. 2010 Oct;16(10):1169-77. 
  58. Rautou PE, Mansouri A, Lebrec D, Durand F, Valla D, Moreau R. Autophagy in liver diseases. J Hepatol. 2010 Dec;53(6):1123-34. 

Scientific summary

Work in the Moreau laboratory concerns the excessive innate immune response to bacterial byproducts, a hallmark of chronic liver diseases such as cirrhosis (which is the 8th most cause of death worldwide). They have shown that immune cells from patients or animals with cirrhosis stimulated with bacterial byproducts, exhibit overactivation of transcription factors (NF-kappaB and AP-1), overproduction of pro-inflammatory cytokines and hypo-production of anti-inflammatory interleukin (IL)-10. This excessive pro-inflammatory response leads to multi-organ failure and death. Their goal is to understand molecular mechanisms responsible for the altered innate immune response in cirrhosis. One question they wish to answer is how negative feed-back pathways (including, Akt/mTOR, STAT3 and CREB) that normally decrease NF-kappaB-dependent transcription are inhibited in cirrhosis. Another question they address is whether deregulation of enzymes modulating histone acetylation and methylation is involved in altered gene expression profile in cirrhotic immune cells. They are also interested in how bacterial byproducts induce failure of cirrhotic livers, addressing the role of impaired liver regeneration, decreased protein synthesis dependent on eIF2apha kinases (PKR and PERK) and mitochondrial dysfunction in animal models of chronic liver diseases. They are also involved in translational research of novel therapeutic approaches aimed to improve prognosis of patients with cirrhosis who are waiting for liver transplantation. Finally, members of the lab including Richard Moreau, are also principal investigators of prospective obersvational studies as well as interventional multicenter randomized double-blind clinical trials.

Image d’exemple